NASDAQ:HALO

Halozyme Therapeutics (HALO) Stock Forecast, Price & News

$32.43

-0.42 (-1.28%)

(As of 05/31/2023 ET)

Compare

Today's Range: $32.41
▼
$33.39
50-Day Range: $30.28
▼
$38.74
52-Week Range: $29.85
▼
$59.46

Volume: 935,619 shs
Average Volume: 1.21 million shs
Market Capitalization: $4.27 billion

P/E Ratio: 24.76
Dividend Yield: N/A
Price Target: $54.78

Halozyme Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.78 Rating Score
Upside/Downside: 68.9% Upside
$54.78 Price Target
Short Interest: Bearish
5.05% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.12
Upright™ Environmental Score
News Sentiment: 1.15
Based on 11 Articles This Week
Insider Trading: Selling Shares
$1.72 M Sold Last Quarter
Proj. Earnings Growth: 44.86%
From $2.43 to $3.52 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.32 out of 5 stars

Medical Sector

3rd out of 1,006 stocks

Biological Products, Except Diagnostic Industry

1st out of 167 stocks

4.4

Analyst's Opinion

Consensus Rating
Halozyme Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $54.78, Halozyme Therapeutics has a forecasted upside of 68.9% from its current price of $32.43.
Amount of Analyst Coverage
Halozyme Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
5.05% of the float of Halozyme Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Halozyme Therapeutics has a short interest ratio ("days to cover") of 4.
Change versus previous month
Short interest in Halozyme Therapeutics has recently increased by 2.33%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Halozyme Therapeutics does not currently pay a dividend.
Dividend Growth
Halozyme Therapeutics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Halozyme Therapeutics has received a 65.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Biopharmaceuticals" and "Medical technology engineering" products. See details.
Environmental Sustainability
The Environmental Impact score for Halozyme Therapeutics is -1.12.

3.4

News and Social Media Coverage

News Sentiment
Halozyme Therapeutics has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Halozyme Therapeutics this week, compared to 4 articles on an average week.
Search Interest
Only 7 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -65% compared to the previous 30 days.
MarketBeat Follows
5 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,719,100.00 in company stock.
Percentage Held by Insiders
Only 2.30% of the stock of Halozyme Therapeutics is held by insiders.
Percentage Held by Institutions
96.32% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

4.4

Earnings and Valuation

Earnings Growth
Earnings for Halozyme Therapeutics are expected to grow by 44.86% in the coming year, from $2.43 to $3.52 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Halozyme Therapeutics is 24.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.60.
Price to Earnings Ratio vs. Sector
The P/E ratio of Halozyme Therapeutics is 24.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.58.
Price to Earnings Growth Ratio
Halozyme Therapeutics has a PEG Ratio of 0.53. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Halozyme Therapeutics has a P/B Ratio of 64.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Stock News Headlines

May 29, 2023 | americanbankingnews.com

Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) PT at $55.30

May 26, 2023 | americanbankingnews.com

Halozyme Therapeutics, Inc. (NASDAQ:HALO) to Post Q2 2023 Earnings of $0.54 Per Share, Zacks Research Forecasts

June 1, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

Thanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.

May 26, 2023 | americanbankingnews.com

Head-To-Head Review: Ginkgo Bioworks (NYSE:DNA) & Halozyme Therapeutics (NASDAQ:HALO)

May 22, 2023 | msn.com

Unusual Put Option Trade in Halozyme Therapeutics (HALO) Worth $170.30K

May 22, 2023 | finance.yahoo.com

Here’s Why Halozyme Therapeutics (HALO) Declined in Q1

May 16, 2023 | finance.yahoo.com

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 63% Above Its Share Price

May 12, 2023 | msn.com

JMP Securities Reiterates Halozyme Therapeutics (HALO) Market Outperform Recommendation

June 1, 2023 | Legacy Research (Affiliate) (Ad)

“Amazon Loophole” could hand you $28,544 in “royalty” payouts

May 12, 2023 | msn.com

Piper Sandler Upgrades Halozyme Therapeutics (HALO)

May 11, 2023 | msn.com

Morgan Stanley Maintains Halozyme Therapeutics (HALO) Overweight Recommendation

May 11, 2023 | americanbankingnews.com

Halozyme Therapeutics (NASDAQ:HALO) Updates FY23 Earnings Guidance

May 11, 2023 | americanbankingnews.com

Halozyme Therapeutics (NASDAQ:HALO) Upgraded to "Overweight" by Piper Sandler

May 10, 2023 | finance.yahoo.com

Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y

May 10, 2023 | markets.businessinsider.com

Positive Report for Halozyme (HALO) from Piper Sandler

May 10, 2023 | finance.yahoo.com

4 big analyst picks: Alcon upgraded to Outperform after Q1 beat | Pro Recap

May 10, 2023 | markets.businessinsider.com

Goldman Sachs Reaffirms Their Buy Rating on Halozyme (HALO)

May 9, 2023 | yahoo.com

HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS

May 9, 2023 | msn.com

Halozyme Therapeutics: Q1 Earnings Insights

May 8, 2023 | msn.com

Halozyme Therapeutics Earnings Preview

May 8, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Halozyme Therapeutics's earnings

May 8, 2023 | americanbankingnews.com

Halozyme Therapeutics (HALO) to Release Earnings on Tuesday

May 4, 2023 | americanbankingnews.com

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Recommendation of "Moderate Buy" by Brokerages

April 26, 2023 | finance.yahoo.com

Halozyme Therapeutics, Inc. (HALO)

April 25, 2023 | finance.yahoo.com

Halozyme To Report First Quarter 2023 Financial and Operating Results

April 25, 2023 | finance.yahoo.com

Halozyme Therapeutics (HALO) Declined on 2023 Profit Outlook

April 25, 2023 | americanbankingnews.com

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Forecasted to Post Q2 2023 Earnings of $0.57 Per Share

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

HALO Company Calendar

Last Earnings: 11/02/2021
Today: 5/31/2023
Next Earnings (Estimated): 8/08/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:HALO
CUSIP: 40637H10
CIK: 1159036
Web: www.halozyme.com
Phone: 858-794-8889
Fax: 858-704-8311
Employees: 145
Year Founded: 1998

Price Target and Rating

Average Stock Price Forecast: $54.78
High Stock Price Forecast: $68.00
Low Stock Price Forecast: $42.00
Forecasted Upside/Downside: +68.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.78
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.31
Trailing P/E Ratio: 24.76
Forward P/E Ratio: 13.35
P/E Growth: 0.53
Net Income: $202.13 million
Net Margins: 25.76%
Pretax Margin: 32.16%
Return on Equity: 184.32%
Return on Assets: 16.05%

Debt

Debt-to-Equity Ratio: 22.69
Current Ratio: 6.69
Quick Ratio: 5.52

Sales & Book Value

Annual Sales: $660.12 million
Price / Sales: 6.47
Cash Flow: $2.53 per share
Price / Cash Flow: 12.80
Book Value: $0.50 per share
Price / Book: 64.86

Miscellaneous

Outstanding Shares: 131,680,000
Free Float: 128,651,000
Market Cap: $4.27 billion
Optionable: Optionable
Beta: 1.21

Social Links

Key Executives

Dr. Helen I. Torley M.B. Ch. B. (Age 59)
M.R.C.P., Pres, CEO & Director
Comp: $1.65M

Dr. Michael J. LaBarre Ph.D. (Age 58)
Chief Technical Officer
Comp: $779.55k

Ms. Nicole LaBrosse (Age 39)
CFO & Director

Ms. Tram Bui
VP of Investor Relations & Corp. Communications

Mr. Mark Snyder Esq.
Gen. Counsel, Chief Compliance Officer & Corp. Sec.

Ms. Amy Marinne Fox
Chief HR Officer

Dr. Steve Knowles MBBS
Chief Medical Officer

Mr. Todd Butler
Chief of Staff to the CEO, VP & Head of Project Management

Dr. Christopher Bryant Ph.D. (Age 61)
Chief Manufacturing Officer & Head of Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

HALO Stock - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" HALO shares.
View HALO analyst ratings or view top-rated stocks.
What is Halozyme Therapeutics' stock price forecast for 2023?: 9 Wall Street research analysts have issued 12 month price targets for Halozyme Therapeutics' shares. Their HALO share price forecasts range from $42.00 to $68.00. On average, they expect the company's stock price to reach $54.78 in the next twelve months. This suggests a possible upside of 68.9% from the stock's current price.
View analysts price targets for HALO or view top-rated stocks among Wall Street analysts.
How have HALO shares performed in 2023?: Halozyme Therapeutics' stock was trading at $56.90 at the start of the year. Since then, HALO shares have decreased by 43.0% and is now trading at $32.43.
View the best growth stocks for 2023 here.
When is Halozyme Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our HALO earnings forecast.
How were Halozyme Therapeutics' earnings last quarter?: Halozyme Therapeutics, Inc. (NASDAQ:HALO) posted its quarterly earnings data on Tuesday, November, 2nd. The biopharmaceutical company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $0.42 by $1.06. The biopharmaceutical company earned $115.83 million during the quarter, compared to analyst estimates of $101.94 million. Halozyme Therapeutics had a net margin of 25.76% and a trailing twelve-month return on equity of 184.32%. During the same quarter in the previous year, the business earned $0.25 EPS.
What ETFs hold Halozyme Therapeutics' stock?: ETFs with the largest weight of Halozyme Therapeutics (NASDAQ:HALO) stock in their portfolio include Future Fund Active ETF (FFND), Invesco Dynamic Biotechnology & Genome ETF (PBE), Goldman Sachs Future Health Care Equity ETF (GDOC), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Invesco S&P MidCap 400 Pure Growth ETF (RFG), BlackRock Future Innovators ETF (BFTR) and Invesco Russell 2000 Dynamic Multifactor ETF (OMFS).
What guidance has Halozyme Therapeutics issued on next quarter's earnings?: Halozyme Therapeutics updated its FY23 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of $2.50-$2.65 for the period, compared to the consensus estimate of $2.58. The company issued revenue guidance of $815-$845 million, compared to the consensus revenue estimate of $832.97 million.
What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?: 12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).
What is Halozyme Therapeutics' stock symbol?: Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."
Who are Halozyme Therapeutics' major shareholders?: Halozyme Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Artisan Partners Limited Partnership (5.16%), Snyder Capital Management L P (3.26%), Macquarie Group Ltd. (2.43%), Geode Capital Management LLC (2.00%), GW&K Investment Management LLC (1.77%) and Charles Schwab Investment Management Inc. (1.25%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, Matthew L Posard, Michael J Labarre and Nicole Labrosse.
View institutional ownership trends.
How do I buy shares of Halozyme Therapeutics?: Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Halozyme Therapeutics' stock price today?: One share of HALO stock can currently be purchased for approximately $32.43.
How much money does Halozyme Therapeutics make?: Halozyme Therapeutics (NASDAQ:HALO) has a market capitalization of $4.27 billion and generates $660.12 million in revenue each year. The biopharmaceutical company earns $202.13 million in net income (profit) each year or $1.31 on an earnings per share basis.
How many employees does Halozyme Therapeutics have?: The company employs 145 workers across the globe.
Does Halozyme Therapeutics have any subsidiaries?: The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More
How can I contact Halozyme Therapeutics?: Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. The official website for the company is www.halozyme.com. The biopharmaceutical company can be reached via phone at 858-794-8889, via email at ir@halozyme.com, or via fax at 858-704-8311.

This page (NASDAQ:HALO) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial